With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

This hormone slows the rate of how the stomach is emptied and regulates blood sugar. Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, ...

The group was conducting a comprehensive investigation into the hack of American telecom companies by Beijing actors dubbed "Salt Typhoon." Described by some lawmakers as the most devastating ...

Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they have used a GLP-1 drug ...

The Department of Homeland Security has terminated all members of advisory committees, including one that has been investigating a major Chinese hack of large US telecom firms. "The Cyber Safety ...

This class of drugs, known as glucagon-like peptide-1 receptor agonists, or GLP-1s, also includes Wegovy and Zepbound. GLP-1s were developed to treat diabetes, but they have become popular weight ...

CLIFTON PARK, N.Y. — Insiya Klapper, who lives in the Capital Region, has experienced a transformative year, shedding 60 pounds with the help of the GLP-1 medication, Zepbound. However ...

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of years thanks to new technologies, former U.S. Treasury Secretary ...

The company's diverse portfolio, including Mounjaro and Zepbound, shows broad growth, with significant contributions from oncology and other therapeutic areas. Long-term growth is supported by new ...

About 140,400 obese patients in Massachusetts were prescribed medications such as Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims ...